JNJ-64140284

JNJ-64140284 is an investigational small molecule drug developed by Johnson & Johnson and its subsidiaries (including Janssen Research & Development) as an inhibitor of the calcium voltage-gated channel auxiliary subunit gamma 8 (CACNG8), also known as TARP γ8. The compound was designed to modulate the activity of AMPA receptors via inhibition of this auxiliary subunit, potentially affecting excitatory neurotransmission in the central nervous system. Its primary development focus was for neurological or psychiatric indications; however, no specific disease indication reached advanced clinical stages. Clinical development included phase 1 studies in healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics after oral administration. As of May 2025, all development has been discontinued[1][2][3].

Other names

AMPARγ8